Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321997
Status:
COMPLETED
Last Update Posted:
2006-05-04
First Post:
2006-05-02
Brief Title:
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium Compared to Sham in Patients With Wet AMD
Sponsor:
Eyetech Pharmaceuticals
Organization:
Eyetech Pharmaceuticals
Study Overview
Official Title:
A PHASE IIIII RANDOMIZED DOUBLE-MASKED CONTROLLED DOSE-RANGING MULTI-CENTER COMPARATIVE TRIAL IN PARALLEL GROUPS TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF EYE001 ANTI-VEGF PEGYLATED APTAMER GIVEN EVERY 6 WEEKS FOR 54 WEEKS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION AMD
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye thereby stabilizing or impriving vision in patients with wet AMD when compared to placebo injections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None